• DiaMedica Therapeutics held its annual general meeting on May 20, 2026.
• Shareholders ratified Baker Tilly US, LLP as independent registered public accounting firm for the year ending Dec. 31, 2026, with the board authorized to set the firm’s remuneration.
• Shareholders backed an amendment to the amended and restated 2019 Omnibus Incentive Plan to increase the share reserve by 3,500,000 shares.
• Seven incumbent directors were returned to the board.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-018106), on May 21, 2026, and is solely responsible for the information contained therein.